Ghiasvand R (2026)
High-Risk Stage II Melanoma: AJCC Staging anomaly or understaging dilemma?
Br J Dermatol (in press)
DOI 10.1093/bjd/ljaf523, PubMed 41483011

Askeland FB, Bugge VH, Rasmussen AM, Lysén A, Haukås E, Moksnes M, Eilertsen AL, Tsykunova G, Eiken BD, Leknes NM, Rolke J, Stavseth V, Samstad E, Hallstensen RF, Szatkowski D, Hansen AA, Nilsen AS, Slørdahl TS, Abdollahi P, Schjesvold F (2025)
Optimizing lenalidomide therapy in renal impairment: analysis of renal response in the prospective REMNANT study in transplant-eligible newly diagnosed multiple myeloma
Blood Cancer J, 15 (1), 214
DOI 10.1038/s41408-025-01407-5, PubMed 41429779

Unal B, Saatcioglu F (2025)
Targeting the unfolded protein response for cancer therapy: mitigating tumor adaptation and immune suppression
Biomark Res, 13 (1), 156
DOI 10.1186/s40364-025-00813-y, PubMed 41372991